ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Heidelberg, Germany, May 11, 2016 -- Affimed N.V. (Nasdaq:AFMD) today announced that on May 18, 2016, the Company will release its financial results for the quarter ended March 31, 2016. The Company's management team will host a conference call to discuss the Company's financial results and recent corporate developments on Wednesday, May 18, 2016 at 8:30 a.m. EST. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 5430699.
| Local - Amsterdam, the Netherlands: | +31 (0) 20 721 9157 |
| Local - Copenhagen, Denmark: | +4532 71 1665 |
| Local – Frankfurt, Germany: | +49 (0) 69 2222 10644 |
| Local - Geneva, Switzerland: | +41 (0) 22 567 5429 |
| Local - London, U.K.: | +44 (0) 20 3427 1930 |
| Local - New York City, U.S.A.: | +1 646 254 3369 |
| Local - Paris, France: | +33 (0) 1 70 48 01 63 |
An audio webcast of the conference call can be accessed in the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the webcast will be available on Affimed's website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
